Navigation Links
Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025

LONDON, November 23, 2015 /PRNewswire/ --

Non-Small Cell Lung Cancer - Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities

Are you interested in the future of lung cancer treatments? Our new analysis forecasts drug revenues for non-small cell lung cancer (NSCLC). There you find outlooks for sales growth. You also explore trends, results, R&D and opportunities, seeing commercial prospects.

Visiongain's report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and revenues those cancer drugs can achieve.

Read on, then, to explore that industry for lung cancer therapies and see what future revenue its expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions
The future looks promising for pharma companies treating those pulmonary cancers. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2015, what revenues and other progress are possible.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing outlooks. You also gain 83 tables, 49 charts and an interview with Novartis.

Our study's purpose is to help your research, analyses and decisions on non-small cell lung cancer, also benefiting your authority and reputation for commercial insight. Stay ahead.

Although no single report covers everything, the following sections show how our new investigation benefits your work.


Forecasts covering the overall world market and segments for treating that lung cancer
Discover in our new analysis revenue predictions to 2025 for NSCLC submarkets at world level. See what is possible for these four therapeutic classes:
• Chemotherapies
• EGFR and ALK inhibitors
• VEGF and VEGFR agents
• Immunotherapy.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and outlooks.

That way you see how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a rising incidence of those lung cancers, the demand for better treatments will continue to bolster that industry and market. Discover what is possible.

You also find sales forecasts by product, exploring how those agents can succeed.

Predictions of leading products' sales - what is possible for those cancer-treating drugs?
How will individual NSCLC medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of these 11 brands:
• Alimta (pemetrexed) by Eli Lilly
• Avastin (bevacizumab) by Roche
• Tarceva (erlotinib) by Roche
• Iressa (gefitinib) by AstraZeneca
• Gilotrif (afatinib) by Boehringer Ingelheim
• Xalkori (crizotinib) by Pfizer
• Abraxane (paclitaxel Protein-Bound) by Celgene
• Taxotere (docetaxel) by Sanofi
• Cyramza (ramucirumab) by Eli Lilly
• Zykadia (ceritinib) by Novartis
• Opdivo (nivolumab) by Bristol-Myers Squibb.

There you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating non-small cell lung cancer. Our work also shows you geographical predictions, by country.

National markets - what outlooks for those anticancer drug revenues?
Advances in the biopharma industry expand the range and use of medicines to treat NSCLC in developed and developing countries.

Our work shows you individual revenue forecasts to 2025 for 11 national markets:
The United States
Germany, France, the United Kingdom, Italy and Spain (EU5 countries)
Brazil, Russia, India and China (BRIC group).

That way you assess regions with highest revenues and potential sales growth. Explore outlooks for treating those diseases, including patients' and healthcare providers' needs.

You also examine developments leading to novel and improved NSCLC treatments.

R&D for those anticancer medicines - trends, innovations and progress
In our study you investigate that oncology - research and development on that pulmonary disease. You examine technological advances, exploring clinical trials and what they mean.

There, in particular, you find discussions of nine R&D pipeline candidates for non-small cell lung cancer:
• Alecensa (alectinib) by Roche
• Vargatef (nintedanib) by Boehringer Ingelheim
• AZD9291 by AstraZeneca
• Rociletinib (CO-1686) by Clovis Oncology
• Keytruda (pembrolizumab) by Merck (MSD)
• Ganetespib (STA-9090) by Synta Pharmaceuticals
• Halaven (eribulin) by Eisai
• Necitumumab by Eli Lilly
• Atezolizumab (MPDL3280A) by Roche.

Researchers' investigation of specific genetic mutations has led to the development of targeted therapies that offer greater hope for the treatment of the late-stage disease.

See, then, what is possible. R&D also gains momentum from rising disease prevalence and other forces making treatments for those pulmonary disorders more widely used.

Events and changes affecting companies treating that lung disease
Explore other issues, too, including these forces shaping the industry and market for that lung disorder:
• Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
• Treatment protocols by stage and for patient populations - maintenance, second-line and third-line therapies
• Regulators' views and cost-effectiveness - challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets

To see a report overview please email Sara Peerun on

• Recent approval for the NSCLC indication - expanding treatment options
• Overcoming patent expiries and competition from generic drugs
• Identification of biomarkers for targeted therapies, advancing treatment protocols.

You also gain SWOT analysis, assessing what drives and restrains that prominent, expanding anticancer drugs market.

See, then, what is possible for leading pharma companies and specialists in biological drugs and related biotechnologies for combating NSCLC.

Leading organisations and overall 2019 market value - what revenues are possible?
Our work predicts the world market for those drugs will reach $8.8bn in 2019. That industry will achieve revenue expansion from 2015 to 2025. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.
That way you assess what organisations hold most potential. For NSCLC therapies you explore drug developers, producers and marketers serving those therapeutic needs.

You also gain an exclusive interview with Novartis. Discover what the future holds for companies in that market, exploring what they say and do, as well as their prospects.

7 ways Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025 helps you
Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:
• Revenues for NSCLC drug therapies to 2025 - assess that overall world market's potential, seeing scope for investments, developments, production and marketing
• Submarket revenues to 2025 covering 4 therapeutic segments - explore treatment categories, seeing their sales outlooks from 2015
• Leading products' sales to 2025 - discover predicted revenues of 11 top brands, seeing how well those medicines can compete and succeed
• National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
• R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and benefit your influence
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else, helping you succeed.

Gain predictions for treating NSCLC, getting information to help you stay ahead
With our independent study you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help lung cancer patients.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study. Our investigation shows you data, trends, opportunities and forecasts for that expanding anticancer market. So avoid missing out - please get our new report here now.

To see a report overview please email Sara Peerun on

To request an exec summary of this report please email Sara Peerun at or call Tel: +44 (0) 20 7336 6100

Or click on

Organisations Mentioned in the Report 




American Cancer Society

American Society of Clinical Oncology





Boehringer Ingelheim

Bristol-Myers Squibb


Chiba University Hospital (Japan)


Clovis Oncology

Committee for Medicinal Products for Human Use (CHMP)


Eli Lilly

EMD Serono

European Commission

European Medicines Agency (EMA)

European Union (EU)

German Institute for Quality and Efficiency in Health Care (IQWiG)


Merck (MSD)

Merck KGaA

Ministry of Health, Labour and Welfare (MHLW, Japan)

National Comprehensive Cancer Network (NCCN)



Oncologic Drugs Advisory Committee (ODAC)




Roche Molecular Systems Inc


Swiss Re

Synta Pharmaceuticals


The Court of Appeal (England)

The European Federation of Pharmaceutical Industries and Associations (EFPIA)

The High Court (England)

The National Health Service (NHS, England)

The National Institute for Health and Care Excellence (NICE)

US Court of Appeals

US Food and Drug Administration (FDA)

World Health Organization (WHO)


To see a report overview please email Sara Peerun on

SOURCE Visiongain
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
2. DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
3. The Market for Non-Small-Cell Lung Cancer Will Grow to $12.7 Billion in 2024, Driven by the Entry of Eleven Novel Drugs
4. Proof-of-concept Study of Fruquintinib in Non-small Cell Lung Cancer Triggers Milestone Payment
5. DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer
6. Study Suggests Non-Invasive Stereotactic Body Radiation Therapy Is Feasible For Treating Large Non-Small Cell Lung Cancer Tumors
7. Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy
8. New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market
9. AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting
10. AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress
11. Global Non-small Cell Lung Cancer Market 2014-2018
Post Your Comments:
(Date:6/19/2019)... ... June 19, 2019 , ... “We sometimes take out teeth for granted,” said Arroyo ... we seldom think about our teeth unless it’s baby’s first tooth, that first visit from ... smile and have a very important role in our overall health. Each tooth is as ...
(Date:6/19/2019)... ... June 19, 2019 , ... INDIGO ... toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein ... vitro toxicology offerings and allows researchers to perform critical toxicology testing previously available ...
(Date:6/18/2019)... ... June 18, 2019 , ... An unexpected and overwhelming public outcry at ... some of its directors to change their minds about supporting SB 276 , ... to protect their patients from vaccine injuries. After hearing testimony from hundreds of parents, ...
Breaking Medicine Technology:
(Date:6/19/2019)... (PRWEB) , ... June 19, 2019 , ... Expanding its ... Causes,” the American Foundation of Savoy Orders raised thousands for Caterina’s Club during its ... on April 6, 2019. This year, $100,000 was donated for the Southern California-based ...
(Date:6/18/2019)... ... , ... HR Maximizer Inc ( ) announced today ... Healthcare HR Association (HHHRA - ). In addition to having ... PageUp, CRC, Alliance Work Partners and Kognito. , Houston Healthcare HR Association, The ...
(Date:6/16/2019)... ... , ... Convoy of Hope continues to celebrate its 25th anniversary. Since its ... around the world. To date, Convoy has worked with more than 46,000 partners to ... possible without the dedication and generosity of churches, organizations, and individuals who believe in ...
(Date:6/13/2019)... ... , ... Endometriosis is a painful, inflammatory disease that occurs when tissue grows outside of the ... Heavy bleeding , Irregular menstruation , Severe cramps , ... the latest and newest treatment protocols in dealing with the symptoms of endometriosis. In the ...
(Date:6/13/2019)... ... June 13, 2019 , ... Pure Ratios, the creator ... delivery company, Driven Deliveries, Inc., the only publicly traded cannabis delivery service in ... population of California with overnight cannabis delivery to major thriving markets such as ...
Breaking Medicine News(10 mins):